Research and analysis

ACRE advice: heart failure gene therapy trial

The Advisory Committee on Releases to the Environment's advice on the release of a genetically modified organism for heart research.


Advice on an application for deliberate release of a GMO: Celladon Corporation

This file may not be suitable for users of assistive technology. Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email Please tell us what format you need. It will help us if you say what assistive technology you use.


This document is the Advisory Committee on Releases to the Environment (ACRE’s) advice to government in considering a request from Celladon Corporation to conduct gene therapy trials. The trial is for research into calcium ion transport in heart failure patients.

The committee decided that the trial would have no risk to human health or the environment, and recommended that the application should be approved.

Published 25 March 2013